Could a common ADHD drug tame attention issues in rare KBG syndrome?

NCT ID NCT06465641

Recruiting now Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether methylphenidate, a standard ADHD medication, can reduce attention and hyperactivity problems in children and adolescents with KBG syndrome, a rare genetic condition often accompanied by ADHD-like symptoms. Participants receive alternating blocks of the drug and a placebo, then complete questionnaires to measure changes in behavior and emotional regulation. The goal is to see if this treatment offers real benefit for this specific group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methylphenidate hydrochloride, a stimulant medication commonly used for ADHD, given in capsules.
What this could lead to: If effective, methylphenidate could offer a safe, targeted way to manage ADHD symptoms in children and teens with KBG syndrome, improving daily functioning.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply broadly. The drug may cause side effects like sleep problems or reduced appetite, and its benefit in this specific genetic condition is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD - COMBINED TYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit-hyperactivity disorder KBG syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD - COMBINED TYPE KBG SYNDROME

Contacts and locations

Locations

Radboud University Medical Center
RECRUITING

Nijmegen, Gelderland, 6500 HB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.